
    
      Primary Trial objective:

      To evaluate the pharmacokinetics and -dynamics of five strengths of COR-1 (10, 40, 80, 160,
      240 mg) in healthy, male volunteers after single intravenous administration

      Secondary objectives:

      To evaluate safety and tolerability by using adverse events (AEs), vital signs including
      blood pressure/pulse rate (BP/PR), electrocardiographic examinations (12 lead ECG),
      evaluation of antibody titer and safety laboratory tests (biochemistry, hematology,
      coagulation, urinalysis)

      Methodology:

      Mono-center, single-blind, dose escalating study with five dose levels (8 subjects on verum
      per dose level, 2 subjects receiving placebo) in a total of 50 volunteers.
    
  